US EditionCStone to Showcase Five Latest Research Achievements at AACR 2025
- CStone will present five innovative cancer treatment candidates at the American Association for Cancer Research Annual Meeting from April 25 to 30, 2025, in Chicago.
- The trispecific antibody CS2009 has shown potential as a first-in-class therapy with enhanced anti-tumor efficacy and is currently in Phase I clinical trials for late-stage cancers.
- CS5006, an antibody-drug conjugate targeting ITGB4, demonstrated effective tumor cell killing in preclinical trials, supporting its clinical development.
- CS5005, a first-in-class antibody-drug conjugate targeting SSTR2, also showed promising anti-tumor activity both in vitro and in vivo.
Insights by Ground AI
Does this summary seem wrong?
33 Articles
33 Articles
All
Left
3
Center
9
Right
journal-republican.com+2 Reposted by 2 other sources
Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting
SHANGHAI, March 26, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of 6 studies as poster presentation at the AACR Annual Meeting to be held in Chicago, USA, from…
·Monticello, United States
Read Full Article
CStone to Showcase Five Latest Research Achievements at AACR 2025
SUZHOU, China, March 25, 2025 /PRNewswire/ -- From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally developed innovative candidates,…
·Pennsylvania, United States
Read Full ArticleCoverage Details
Total News Sources33
Leaning Left3Leaning Right0Center9Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 25%
C 75%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
